Section 1: The Clinical Approach
Section 2: Primary Headaches

The original description of this disorder was termed SUNCT, short-lasting unilateral neuralgiform attacks with conjunctival injection and tearing ().
Conjunctival injection and tearing (lacrimation) are the most common autonomic symptoms in all the TACs (; ; ; ; Kudrow, 1980; ; ).
The terminology SUNA was proposed based on the fact that a number of patients were noted to lack one or both of these symptoms () (). The distinction remains within the ICHD classification. From a clinical perspective, management remains the same.
The distinction remains within the ICHD classification. Ïã½¹ÊÓÆµ recommends this as a research tool and for current clinical purposes will adopt the terminology of SUNA to encompass both groups ().
SUNCT/SUNA is rare (; )
The mean age of onset is 48 years with a slight male preponderance 1.5 ().
The attacks are the shortest and most frequent of all the TACs. Attacks can be either spontaneous or induced by cutaneous triggers. Mean duration is about one minute (range 1-600 seconds) with frequency up to 30 attacks in an hour ().
The character of the attacks can vary: attacks can occur in single stabs, a group of stabs or a long attack with a ‘saw-tooth’ pattern of stabs between which the pain does not return to baseline. Other features of TACs may be present, such as agitation. SUNCT/SUNA can be misdiagnosed as Trigeminal Neuralgia. However, the location of the pain, autonomic features, duration of attacks and spontaneity of attacks in SUNCT/SUNA, differentiate between the two (see Section 2.4.3.2 Appendix 2: Differential diagnosis of the trigeminal autonomic cephalalgias and trigeminal neuralgia).
There are no RCTs for preventive treatment in SUNCT/SUNA.
Because of the short attack duration there are no effective acute treatments in SUNCT/SUNA ().
The most effective reported treatment is lamotrigine with dose range up to 400 mg. Topiramate may be effective in SUNCT (Cohen et al., 2007). Carbamazepine and gabapentin may also be effective (; ; )


We use cookies to allow us to better understand how the site is used. By continuing to use this site, you consent to this policy. Click to learn more